Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 5th Annual Evercore ISI HealthCONx Conference November 29, 2022 11:45 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations John Lin - Senior Vice President, Immuno-Oncology & Head, Bi-Specifics Neil Stahl - Executive Vice President, Research & Development Conference Call Participants Josh Schimmer - Evercore ISI Josh Schimmer All right. Welcome, everyone. This is Josh Schimmer from Evercore ISI biotech team. Pleased to welcome. From Regener ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Jefferies London Healthcare Conference November 16, 2022 10:15 AM ET Company Participants Ryan Crowe - VP, IR Robert Landry - EVP, Finance & CFO Conference Call Participants Akash Tewari - Jefferies Akash Tewari All right. Well, good afternoon. Day two of the London Healthcare Conference. My name is Akash Tewari. I'm one of the therapeutic analysts here. I hope you guys are all enjoying yourself. I'll tell you, it's wonderful to see everyone back, it really is. ...

Regeneron Pharmaceuticals, Inc. (AAPL) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations Leonard Schleifer - President, Chief Executive Officer George Yancopoulos - President, Chief Scientific Officer Marion McCourt - Executive Vice President, Head of Commercial Robert Landry - Executive Vice President, Chief Financial Officer Conference Call Participants Evan Seigerman - BMO Tyler Van Buren - Cowen Salveen Richter - Goldman Sac ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 0-19034 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 1 ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations Leonard Schleifer - President, Chief Executive Officer George Yancopoulos - President, Chief Scientific Officer Marion McCourt - Executive Vice President, Head of Commercial Robert Landry - Executive Vice President, Chief Financial Officer Conference Call Participants Mohit Bansal - Wells Fargo Evan Seigerman - BMO Capital Markets Tyler ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 0-19034 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 13-344 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 0-19034 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 13-34 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 0-19034 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 13-3444607 ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2021 Results Conference Call February 4, 2022 8:30 AM ET Company Participants Mark Hudson - Director, IR Dr. Len Schleifer - Co-Founder, President, CEO & Executive Director Dr. George Yancopoulos - Co-Founder, President & Chief Scientific Officer Marion McCourt - EVP and Head of Commercial Bob Landry - EVP & CFO Conference Call Participants Evan Seigerman - BMO Carter Gould - Barclays Tyler Van Buren - Cowen Salveen Richter - Goldman Sachs Ronny Gal - Allianc ...